A carregar...
Combination of KRAS Gene Silencing and PI3K Inhibition for Ovarian Cancer Treatment
The phosphoinositide 3-kinase (PI3K) and RAS signaling pathways are frequently co-activated and altered during oncogenesis. Owing to their regulatory cross-talk, the early attempts of targeting only one pathway have mostly ended up promoting the development of drug resistance. Here, we propose using...
Na minha lista:
| Publicado no: | J Control Release |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7056267/ https://ncbi.nlm.nih.gov/pubmed/31838203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2019.12.019 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|